Table 3.
Association of the preoperative plasma uPAR forms with clinical outcome (univariate analyses).
| Patient Characteristics | RFS a | CSS a | OS a | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-Value | HR | 95% CI | p-Value | HR | 95% CI | p-Value | |
| uPAR levels log transformed base 2 | |||||||||
| uPAR (I−III) | 3.11 | 1.03–9.44 | 0.045 | 3.41 | 1.00–11.67 | 0.051 | 3.85 | 1.26–11.72 | 0.018 |
| uPAR (I−III) + uPAR (II−III) | 4.20 | 1.39–12.67 | 0.011 | 4.03 | 1.37–11.87 | 0.012 | 4.95 | 1.90–12.92 | 0.001 |
| uPAR (I) | 2.26 | 1.45–3.50 | 0.0003 | 2.63 | 1.58–4.38 | 0.0002 | 2.56 | 1.64–4.00 | 0.0001 |
| uPAR levels dichotomised according to reference intervals b | |||||||||
| uPAR (I−III) | 1.90 | 0.87–4.17 | 0.109 | 1.74 | 0.74–4.09 | 0.207 | 1.97 | 0.93–4.20 | 0.078 |
| uPAR (I−III) + uPAR (II−III) | 2.02 | 0.89–4.56 | 0.093 | 2.19 | 0.91–5.30 | 0.081 | 2.93 | 1.37–6.27 | 0.006 |
| uPAR (I) | 1.62 | 0.74–3.56 | 0.226 | 1.57 | 0.67–3.69 | 0.303 | 1,84 | 0.86–3.91 | 0.115 |
| Clinicopathological characteristics | |||||||||
| Age pr. 10 yr. age diff. | 1.00 | 0.63–1.60 | 1.000 | 0.87 | 0.53–1.44 | 0.594 | 0.98 | 0.62–1.54 | 0.922 |
| Gender | |||||||||
| Female vs. Male | 3.60 | 1.26–8.00 | 1.00 | 3.73 | 1.57–8.85 | 0.003 | 2.35 | 1.05–5.24 | 0.038 |
| Tumor stage (cystectomy specimen) | |||||||||
| pT ≥ pT3 pN0 vs. pT ≤ pT2 pN0 | 8.07 | 2.79–23.31 | 0.0001 | 9.00 | 2.94–27.58 | 0.0001 | 5.30 | 2.15–13.10 | 0.0003 |
| pTany pN+ vs. pT ≤ pT2 pN0 | 17.51 | 6.38–48.05 | <0.0001 | 11.71 | 3.08–35.93 | <0.0001 | 6.32 | 2.48–16.12 | 0.0001 |
| Lymph node metastasis | |||||||||
| Yes vs. No | 8.62 | 3.85–19.23 | 0.0001 | 5.26 | 2.17–12.66 | 0.0002 | 3.85 | 1.67–8.85 | 0.0015 |
| Pathologic grade | |||||||||
| HG vs. LG | NA c | 1.00 | NA c | 1.00 | NA c | 0.99 | |||
| Vascular invasion | |||||||||
| Yes vs. No | 6.99 | 3.09–15.87 | 0.0001 | 5.20 | 2.15–12.66 | 0.0003 | 3.86 | 1.68–8.93 | 0.002 |
| Resection margin | |||||||||
| Positive vs. Negative | 6.80 | 2.54–18.18 | 0.0001 | 5.13 | 1.72–15.38 | 0.003 | 3.65 | 1.26–10.64 | 0.017 |
| Neoadjuvant chemotherapy | |||||||||
| Yes vs. No | 0.71 | 0.27–1.89 | 0.49 | 0.95 | 0.35–2.61 | 0.92 | 1.41 | 0.61–3.26 | 0.42 |
a Analyses have been done using the Cox proportional hazards model, and the results are presented by the HR with 95% CI. The reference levels are those with an expected good prognosis, but for neoadjuvant therapy, the reference is those not receiving neoadjuvant therapy. b Patients were dichotomized using the 95th percentile upper limit of the previous determined reference intervals for the different uPAR forms. c NA: not accessible because of the limited number of patients with uPAR negative combined with the low event rate. LG = low grade; HG = high grade.